SpyGlass Pharma (SGP) Liabilities and Shareholders Equity (2024 - 2026)
SpyGlass Pharma (SGP) posted quarterly Liabilities and Shareholders Equity of $115.9 million for Q4 2025, up 396.9% year-over-year from $23.3 million in Q4 2024, and up 396.9% quarter-over-quarter from $23.3 million in Q4 2024.
Powered by 
Analysis
SpyGlass Pharma (SGP) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
SpyGlass Pharma (SGP) has reported Liabilities and Shareholders Equity for 2 consecutive years, with $115.9 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | SpyGlass Pharma | 973.76 Mn | 973.76 Mn | - | 243.43 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 243.43 Mn |
| Dec 31, 2025 | 115.87 Mn |
| Dec 31, 2024 | 23.32 Mn |